61 Biggest Movers From Yesterday
Gainers
BSQUARE Corporation (NASDAQ: BSQR) shares climbed 77.1% to close at $7.05 on Tuesday on abnormally-high volume. The company’s stock dropped around 10% on Friday.
42 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Orbsat Corp. (NASDAQ: OSAT) shares jumped 74% to $9.47.
BSQUARE Corporation (NASDAQ: BSQR) shares jumped 48.2% to $5.90 after dropping around 10% on Friday.
Piper Sandler Initiates Coverage On Tempest Therapeutics with Overweight Rating, Announces Price Target of $23
Piper Sandler analyst Edward Tenthoff initiates coverage on Tempest Therapeutics (NASDAQ:TPST) with a Overweight rating and announces Price Target of $23.
The Daily Biotech Pulse: Iterum’s Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 1)
72 Biggest Movers From Yesterday
Gainers
Pop Culture Group Co., Ltd (NASDAQ: CPOP) shares jumped 405% to close at $30.30 on Wednesday after the company priced its IPO at $6 per share.
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 29)
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 28)
61 Biggest Movers From Yesterday
Gainers
Marin Software Incorporated (NASDAQ: MRIN) surged 96.9% to close at $7.50. Marin Software, last week, announced it has added the ability to manage Instacart Ads to its flagship MarinOne platform.
44 Stocks Moving In Monday’s Mid-Day Session
Gainers
Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares climbed 43.5% to $127.44 after the company announced positive clinical data for its CRISPR therapy.